Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial
Identifieur interne : 001507 ( Istex/Corpus ); précédent : 001506; suivant : 001508Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial
Auteurs : Alexandre Abizaid ; Áurea J. Chaves ; Martin B. Leon ; Karl Hauptmann ; Roxana Mehran ; Alexandra J. Lansky ; William Baumbach ; Hari Shankar ; Ralf Muller ; Fausto Feres ; Amanda G. M. R. Sousa ; J. Eduardo Sousa ; Eberhard GrubeSource :
- Catheterization and Cardiovascular Interventions [ 1522-1946 ] ; 2007-11-01.
English descriptors
Abstract
Objectives: The ETHOS I trial was the first in‐human experience evaluating the safety and efficacy of two different release formulations of the 17‐β estradiol‐eluting R‐Stent™ versus uncoated control stents for the treatment of patients with single de novo native coronary lesions. Background: Estrogens were reported to inhibit neointimal proliferation and to accelerate endothelial regeneration after coronary angioplasty and thus could be an ideal compound to deliver on a stent for the purpose of reducing in‐stent restenosis. Methods: Ninety‐five patients were randomized to receive a slow‐release (n = 32) or the moderate release (n = 31) formulations or the bare metal stent (n = 32). The primary end point was the 6‐month percent in‐stent volume obstruction by intravascular ultrasound (IVUS). Results: Diabetes was present in 29.5% of patients; the mean reference vessel diameter was 2.90 mm; and the mean lesion length was 13.5 mm. Primary endpoint, 6‐month percent in‐stent volume obstruction by IVUS, did not differ significantly between the 3 groups (31% ± 14%, 33% ± 11%, and 31% ± 14%, P = 0.83). Secondary endpoints also did not differ significantly between the groups including 6‐month rates of in‐lesion binary angiographic restenosis (13.3%, 14.3%, and 12.5%, P = 0.98), in‐stent late loss (0.82 ± 0.49 mm, 0.86 ± 0.53 mm, and 0.84 ± 0.46 mm, P = 0.97), target lesion revascularization (12.5%, 6.9%, and 6.5%, P = 0.64), and major adverse cardiac events (18.8%, 10.3%, and 6.5%, P = 0.31). Conclusions: In this first‐in‐man randomized trial, the 17‐β estradiol‐eluting R‐Stent™, in either slow‐ or moderate‐release formulations, was well‐tolerated, but showed no benefit for treatment of coronary lesions when compared to controls. © 2007 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/ccd.21210
Links to Exploration step
ISTEX:2B9B796433B5D2406CAD4C00FB1CF8D69105D149Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial</title><author><name sortKey="Abizaid, Alexandre" sort="Abizaid, Alexandre" uniqKey="Abizaid A" first="Alexandre" last="Abizaid">Alexandre Abizaid</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, Av Dr Dante Pazzanese, 500, São Paulo 04012‐180, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Chaves, Aurea J" sort="Chaves, Aurea J" uniqKey="Chaves A" first="Áurea J." last="Chaves">Áurea J. Chaves</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Leon, Martin B" sort="Leon, Martin B" uniqKey="Leon M" first="Martin B." last="Leon">Martin B. Leon</name><affiliation><mods:affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</mods:affiliation></affiliation><affiliation><mods:affiliation>Cardiovascular Research Foundation, New York, New York</mods:affiliation></affiliation></author><author><name sortKey="Hauptmann, Karl" sort="Hauptmann, Karl" uniqKey="Hauptmann K" first="Karl" last="Hauptmann">Karl Hauptmann</name><affiliation><mods:affiliation>Krankenhaus der Barmherzigen Brüder, Trier, Germany</mods:affiliation></affiliation></author><author><name sortKey="Mehran, Roxana" sort="Mehran, Roxana" uniqKey="Mehran R" first="Roxana" last="Mehran">Roxana Mehran</name><affiliation><mods:affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</mods:affiliation></affiliation><affiliation><mods:affiliation>Cardiovascular Research Foundation, New York, New York</mods:affiliation></affiliation></author><author><name sortKey="Lansky, Alexandra J" sort="Lansky, Alexandra J" uniqKey="Lansky A" first="Alexandra J." last="Lansky">Alexandra J. Lansky</name><affiliation><mods:affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</mods:affiliation></affiliation><affiliation><mods:affiliation>Cardiovascular Research Foundation, New York, New York</mods:affiliation></affiliation></author><author><name sortKey="Baumbach, William" sort="Baumbach, William" uniqKey="Baumbach W" first="William" last="Baumbach">William Baumbach</name><affiliation><mods:affiliation>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</mods:affiliation></affiliation></author><author><name sortKey="Shankar, Hari" sort="Shankar, Hari" uniqKey="Shankar H" first="Hari" last="Shankar">Hari Shankar</name><affiliation><mods:affiliation>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</mods:affiliation></affiliation></author><author><name sortKey="Muller, Ralf" sort="Muller, Ralf" uniqKey="Muller R" first="Ralf" last="Muller">Ralf Muller</name><affiliation><mods:affiliation>Heart Center Siegburg, Siegburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Feres, Fausto" sort="Feres, Fausto" uniqKey="Feres F" first="Fausto" last="Feres">Fausto Feres</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Sousa, Amanda G M R" sort="Sousa, Amanda G M R" uniqKey="Sousa A" first="Amanda G. M. R." last="Sousa">Amanda G. M. R. Sousa</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Sousa, J Eduardo" sort="Sousa, J Eduardo" uniqKey="Sousa J" first="J. Eduardo" last="Sousa">J. Eduardo Sousa</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Grube, Eberhard" sort="Grube, Eberhard" uniqKey="Grube E" first="Eberhard" last="Grube">Eberhard Grube</name><affiliation><mods:affiliation>Heart Center Siegburg, Siegburg, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2B9B796433B5D2406CAD4C00FB1CF8D69105D149</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/ccd.21210</idno><idno type="url">https://api.istex.fr/document/2B9B796433B5D2406CAD4C00FB1CF8D69105D149/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001507</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001507</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial</title><author><name sortKey="Abizaid, Alexandre" sort="Abizaid, Alexandre" uniqKey="Abizaid A" first="Alexandre" last="Abizaid">Alexandre Abizaid</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, Av Dr Dante Pazzanese, 500, São Paulo 04012‐180, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Chaves, Aurea J" sort="Chaves, Aurea J" uniqKey="Chaves A" first="Áurea J." last="Chaves">Áurea J. Chaves</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Leon, Martin B" sort="Leon, Martin B" uniqKey="Leon M" first="Martin B." last="Leon">Martin B. Leon</name><affiliation><mods:affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</mods:affiliation></affiliation><affiliation><mods:affiliation>Cardiovascular Research Foundation, New York, New York</mods:affiliation></affiliation></author><author><name sortKey="Hauptmann, Karl" sort="Hauptmann, Karl" uniqKey="Hauptmann K" first="Karl" last="Hauptmann">Karl Hauptmann</name><affiliation><mods:affiliation>Krankenhaus der Barmherzigen Brüder, Trier, Germany</mods:affiliation></affiliation></author><author><name sortKey="Mehran, Roxana" sort="Mehran, Roxana" uniqKey="Mehran R" first="Roxana" last="Mehran">Roxana Mehran</name><affiliation><mods:affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</mods:affiliation></affiliation><affiliation><mods:affiliation>Cardiovascular Research Foundation, New York, New York</mods:affiliation></affiliation></author><author><name sortKey="Lansky, Alexandra J" sort="Lansky, Alexandra J" uniqKey="Lansky A" first="Alexandra J." last="Lansky">Alexandra J. Lansky</name><affiliation><mods:affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</mods:affiliation></affiliation><affiliation><mods:affiliation>Cardiovascular Research Foundation, New York, New York</mods:affiliation></affiliation></author><author><name sortKey="Baumbach, William" sort="Baumbach, William" uniqKey="Baumbach W" first="William" last="Baumbach">William Baumbach</name><affiliation><mods:affiliation>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</mods:affiliation></affiliation></author><author><name sortKey="Shankar, Hari" sort="Shankar, Hari" uniqKey="Shankar H" first="Hari" last="Shankar">Hari Shankar</name><affiliation><mods:affiliation>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</mods:affiliation></affiliation></author><author><name sortKey="Muller, Ralf" sort="Muller, Ralf" uniqKey="Muller R" first="Ralf" last="Muller">Ralf Muller</name><affiliation><mods:affiliation>Heart Center Siegburg, Siegburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Feres, Fausto" sort="Feres, Fausto" uniqKey="Feres F" first="Fausto" last="Feres">Fausto Feres</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Sousa, Amanda G M R" sort="Sousa, Amanda G M R" uniqKey="Sousa A" first="Amanda G. M. R." last="Sousa">Amanda G. M. R. Sousa</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Sousa, J Eduardo" sort="Sousa, J Eduardo" uniqKey="Sousa J" first="J. Eduardo" last="Sousa">J. Eduardo Sousa</name><affiliation><mods:affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Grube, Eberhard" sort="Grube, Eberhard" uniqKey="Grube E" first="Eberhard" last="Grube">Eberhard Grube</name><affiliation><mods:affiliation>Heart Center Siegburg, Siegburg, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Catheterization and Cardiovascular Interventions</title><title level="j" type="abbrev">Cathet. Cardiovasc. Intervent.</title><idno type="ISSN">1522-1946</idno><idno type="eISSN">1522-726X</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-11-01">2007-11-01</date><biblScope unit="volume">70</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="654">654</biblScope><biblScope unit="page" to="660">660</biblScope></imprint><idno type="ISSN">1522-1946</idno></series><idno type="istex">2B9B796433B5D2406CAD4C00FB1CF8D69105D149</idno><idno type="DOI">10.1002/ccd.21210</idno><idno type="ArticleID">CCD21210</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1522-1946</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>coronary artery disease</term><term>drug‐eluting stents</term><term>restenosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives: The ETHOS I trial was the first in‐human experience evaluating the safety and efficacy of two different release formulations of the 17‐β estradiol‐eluting R‐Stent™ versus uncoated control stents for the treatment of patients with single de novo native coronary lesions. Background: Estrogens were reported to inhibit neointimal proliferation and to accelerate endothelial regeneration after coronary angioplasty and thus could be an ideal compound to deliver on a stent for the purpose of reducing in‐stent restenosis. Methods: Ninety‐five patients were randomized to receive a slow‐release (n = 32) or the moderate release (n = 31) formulations or the bare metal stent (n = 32). The primary end point was the 6‐month percent in‐stent volume obstruction by intravascular ultrasound (IVUS). Results: Diabetes was present in 29.5% of patients; the mean reference vessel diameter was 2.90 mm; and the mean lesion length was 13.5 mm. Primary endpoint, 6‐month percent in‐stent volume obstruction by IVUS, did not differ significantly between the 3 groups (31% ± 14%, 33% ± 11%, and 31% ± 14%, P = 0.83). Secondary endpoints also did not differ significantly between the groups including 6‐month rates of in‐lesion binary angiographic restenosis (13.3%, 14.3%, and 12.5%, P = 0.98), in‐stent late loss (0.82 ± 0.49 mm, 0.86 ± 0.53 mm, and 0.84 ± 0.46 mm, P = 0.97), target lesion revascularization (12.5%, 6.9%, and 6.5%, P = 0.64), and major adverse cardiac events (18.8%, 10.3%, and 6.5%, P = 0.31). Conclusions: In this first‐in‐man randomized trial, the 17‐β estradiol‐eluting R‐Stent™, in either slow‐ or moderate‐release formulations, was well‐tolerated, but showed no benefit for treatment of coronary lesions when compared to controls. © 2007 Wiley‐Liss, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Alexandre Abizaid MD, PhD</name><affiliations><json:string>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</json:string><json:string>Instituto Dante Pazzanese de Cardiologia, Av Dr Dante Pazzanese, 500, São Paulo 04012‐180, Brazil</json:string></affiliations></json:item><json:item><name>Áurea J. Chaves MD, PhD</name><affiliations><json:string>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</json:string></affiliations></json:item><json:item><name>Martin B. Leon MD</name><affiliations><json:string>College of Physicians and Surgeons, Columbia University, New York, New York</json:string><json:string>Cardiovascular Research Foundation, New York, New York</json:string></affiliations></json:item><json:item><name>Karl Hauptmann MD</name><affiliations><json:string>Krankenhaus der Barmherzigen Brüder, Trier, Germany</json:string></affiliations></json:item><json:item><name>Roxana Mehran MD</name><affiliations><json:string>College of Physicians and Surgeons, Columbia University, New York, New York</json:string><json:string>Cardiovascular Research Foundation, New York, New York</json:string></affiliations></json:item><json:item><name>Alexandra J. Lansky MD</name><affiliations><json:string>College of Physicians and Surgeons, Columbia University, New York, New York</json:string><json:string>Cardiovascular Research Foundation, New York, New York</json:string></affiliations></json:item><json:item><name>William Baumbach PhD</name><affiliations><json:string>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</json:string></affiliations></json:item><json:item><name>Hari Shankar PhD</name><affiliations><json:string>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</json:string></affiliations></json:item><json:item><name>Ralf Muller MD</name><affiliations><json:string>Heart Center Siegburg, Siegburg, Germany</json:string></affiliations></json:item><json:item><name>Fausto Feres MD, PhD</name><affiliations><json:string>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</json:string></affiliations></json:item><json:item><name>Amanda G.M.R. Sousa MD, PhD</name><affiliations><json:string>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</json:string></affiliations></json:item><json:item><name>J. Eduardo Sousa MD, PhD</name><affiliations><json:string>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</json:string></affiliations></json:item><json:item><name>Eberhard Grube MD</name><affiliations><json:string>Heart Center Siegburg, Siegburg, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>coronary artery disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>drug‐eluting stents</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>restenosis</value></json:item></subject><articleId><json:string>CCD21210</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Objectives: The ETHOS I trial was the first in‐human experience evaluating the safety and efficacy of two different release formulations of the 17‐β estradiol‐eluting R‐Stent™ versus uncoated control stents for the treatment of patients with single de novo native coronary lesions. Background: Estrogens were reported to inhibit neointimal proliferation and to accelerate endothelial regeneration after coronary angioplasty and thus could be an ideal compound to deliver on a stent for the purpose of reducing in‐stent restenosis. Methods: Ninety‐five patients were randomized to receive a slow‐release (n = 32) or the moderate release (n = 31) formulations or the bare metal stent (n = 32). The primary end point was the 6‐month percent in‐stent volume obstruction by intravascular ultrasound (IVUS). Results: Diabetes was present in 29.5% of patients; the mean reference vessel diameter was 2.90 mm; and the mean lesion length was 13.5 mm. Primary endpoint, 6‐month percent in‐stent volume obstruction by IVUS, did not differ significantly between the 3 groups (31% ± 14%, 33% ± 11%, and 31% ± 14%, P = 0.83). Secondary endpoints also did not differ significantly between the groups including 6‐month rates of in‐lesion binary angiographic restenosis (13.3%, 14.3%, and 12.5%, P = 0.98), in‐stent late loss (0.82 ± 0.49 mm, 0.86 ± 0.53 mm, and 0.84 ± 0.46 mm, P = 0.97), target lesion revascularization (12.5%, 6.9%, and 6.5%, P = 0.64), and major adverse cardiac events (18.8%, 10.3%, and 6.5%, P = 0.31). Conclusions: In this first‐in‐man randomized trial, the 17‐β estradiol‐eluting R‐Stent™, in either slow‐ or moderate‐release formulations, was well‐tolerated, but showed no benefit for treatment of coronary lesions when compared to controls. © 2007 Wiley‐Liss, Inc.</abstract><qualityIndicators><score>6.833</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1774</abstractCharCount><pdfWordCount>3833</pdfWordCount><pdfCharCount>25803</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>274</abstractWordCount></qualityIndicators><title>Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial</title><refBibs><json:item><author><json:item><name>G Weisz</name></json:item><json:item><name>MB Leon</name></json:item><json:item><name>DR Holmes</name></json:item><json:item><name>DJ Kereiakes</name></json:item><json:item><name>MR Clark</name></json:item><json:item><name>BM Cohen</name></json:item><json:item><name>SG Ellis</name></json:item><json:item><name>P Coleman</name></json:item><json:item><name>C Hill</name></json:item><json:item><name>C Shi</name></json:item><json:item><name>DE Cutlip</name></json:item><json:item><name>RE Kuntz</name></json:item><json:item><name>JW Moses</name></json:item></author><host><volume>47</volume><pages><last>1355</last><first>1350</first></pages><author></author><title>J Am Coll Cardiol</title></host><title>Two‐year outcomes after sirolimus‐eluting stent implantation: Results from the Sirolimus‐Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial</title></json:item><json:item><author><json:item><name>J Aoki</name></json:item><json:item><name>A Colombo</name></json:item><json:item><name>D Dudek</name></json:item><json:item><name>AP Banning</name></json:item><json:item><name>J Drzewiecki</name></json:item><json:item><name>K Zmudka</name></json:item><json:item><name>F Schiele</name></json:item><json:item><name>ME Russell</name></json:item><json:item><name>J Koglin</name></json:item><json:item><name>PW Serruys</name></json:item></author><host><volume>112</volume><pages><last>3883</last><first>3876</first></pages><author></author><title>Circulation</title></host><title>Peristent remodeling and neointimal suppression 2 years after polymer‐based, paclitaxel‐eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study</title></json:item><json:item><author><json:item><name>M Joner</name></json:item><json:item><name>AV Finn</name></json:item><json:item><name>A Farb</name></json:item><json:item><name>EK Mont</name></json:item><json:item><name>FD Kolodgie</name></json:item><json:item><name>E Ladich</name></json:item><json:item><name>R Kutys</name></json:item><json:item><name>K Skorija</name></json:item><json:item><name>HK Gold</name></json:item><json:item><name>R Virmani</name></json:item></author><host><volume>48</volume><pages><last>202</last><first>193</first></pages><author></author><title>J Am Coll Cardiol</title></host><title>Pathology of drug‐eluting stents in humans: delayed healing and late thrombotic risk</title></json:item><json:item><author><json:item><name>SJ Chen</name></json:item><json:item><name>H Li</name></json:item><json:item><name>J Durand</name></json:item><json:item><name>S Oparil</name></json:item><json:item><name>YF Chen</name></json:item></author><host><volume>93</volume><pages><last>584</last><first>577</first></pages><author></author><title>Circulation</title></host><title>Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery</title></json:item><json:item><author><json:item><name>L Brouchet</name></json:item><json:item><name>A Krust</name></json:item><json:item><name>S Dupont</name></json:item><json:item><name>P Chambon</name></json:item><json:item><name>F Bayard</name></json:item><json:item><name>JF Arnal</name></json:item></author><host><volume>103</volume><pages><last>428</last><first>423</first></pages><author></author><title>Circulation</title></host><title>Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor‐alpha but not estrogen receptor‐beta</title></json:item><json:item><author><json:item><name>A Abizaid</name></json:item><json:item><name>M Albertal</name></json:item><json:item><name>MA Costa</name></json:item><json:item><name>AS Abizaid</name></json:item><json:item><name>R Staico</name></json:item><json:item><name>F Feres</name></json:item><json:item><name>LA Mattos</name></json:item><json:item><name>AGMR Sousa</name></json:item><json:item><name>J Moses</name></json:item><json:item><name>N Kipshidize</name></json:item><json:item><name>GS Roubin</name></json:item><json:item><name>R Mehran</name></json:item><json:item><name>G New</name></json:item><json:item><name>MB Leon</name></json:item><json:item><name>JE Sousa</name></json:item></author><host><volume>43</volume><pages><last>1121</last><first>1118</first></pages><author></author><title>J Am Coll Cardiol</title></host><title>First human experience with the 17‐β‐estradiol‐eluting stent: The estrogen and stents to eliminate restenosis (EASTER) trial</title></json:item><json:item><author><json:item><name>ME Mendelsohn</name></json:item><json:item><name>RH Karas</name></json:item></author><host><volume>340</volume><pages><last>1811</last><first>1801</first></pages><author></author><title>N Engl J Med</title></host><title>The protective effects of estrogen on the cardiovascular system</title></json:item><json:item><author><json:item><name>L Mauri</name></json:item><json:item><name>W Hsieh</name></json:item><json:item><name>JM Massaro</name></json:item><json:item><name>KKL Ho</name></json:item><json:item><name>R D'Agostino</name></json:item><json:item><name>DE Cutlip</name></json:item></author><host><volume>356</volume><pages><last>1029</last><first>1020</first></pages><author></author><title>N Engl J Med</title></host><title>Stent thrombosis in randomized clinical trials of drug‐ eluting stents</title></json:item><json:item><author><json:item><name>GS Mintz</name></json:item></author><host><pages><last>400</last><first>299</first></pages><author></author><title>Intravascular Ultrasound</title></host><title>Mechanisms, prevention, and treatment of restenosis</title></json:item><json:item><author><json:item><name>FD Kolodgie</name></json:item><json:item><name>A Jacob</name></json:item><json:item><name>PS Wilson</name></json:item><json:item><name>GC Carlson</name></json:item><json:item><name>A Farb</name></json:item><json:item><name>A Verma</name></json:item><json:item><name>R Virmani</name></json:item></author><host><volume>148</volume><pages><last>976</last><first>969</first></pages><author></author><title>Am J Pathol</title></host><title>Estradiol attenuates directed migration of vascular smooth muscle cells in vitro</title></json:item><json:item><author><json:item><name>G Li</name></json:item><json:item><name>YF Chen</name></json:item><json:item><name>GL Greene</name></json:item><json:item><name>S Oparil</name></json:item><json:item><name>JA Thompson</name></json:item></author><host><volume>100</volume><pages><last>1645</last><first>1639</first></pages><author></author><title>Circulation</title></host><title>Estrogen inhibits vascular smooth muscle cell‐dependent adventitial fibroblast migration in vitro</title></json:item><json:item><author><json:item><name>T Mori</name></json:item><json:item><name>J Durand</name></json:item><json:item><name>Y Chen</name></json:item><json:item><name>JA Thompson</name></json:item><json:item><name>S Bakir</name></json:item><json:item><name>S Oparil</name></json:item></author><host><volume>85</volume><pages><last>1279</last><first>1276</first></pages><author></author><title>Am J Cardiol</title></host><title>Effects of short‐term estrogen treatment on the neointimal response to balloon injury of rat carotid artery</title></json:item><json:item><author><json:item><name>S Oparil</name></json:item><json:item><name>SJ Chen</name></json:item><json:item><name>YF Chen</name></json:item><json:item><name>J Durand</name></json:item><json:item><name>L Allen</name></json:item><json:item><name>JA Thompson</name></json:item></author><host><volume>44</volume><pages><last>614</last><first>608</first></pages><author></author><title>Cardiovasc Res</title></host><title>Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries</title></json:item><json:item><author><json:item><name>TR Sullivan Jr</name></json:item><json:item><name>RH Karas</name></json:item><json:item><name>M Aronovitz</name></json:item><json:item><name>GT Faller</name></json:item><json:item><name>JP Ziar</name></json:item><json:item><name>JJ Smith</name></json:item><json:item><name>TF O'Donnell Jr</name></json:item><json:item><name>ME Mendelsohn</name></json:item></author><host><volume>96</volume><pages><last>2488</last><first>2482</first></pages><author></author><title>J Clin Invest</title></host><title>Estrogen inhibits the response‐to‐injury in a mouse carotid artery model</title></json:item><json:item><author><json:item><name>GS Ashcroft</name></json:item><json:item><name>J Dodsworth</name></json:item><json:item><name>E van Boxtel</name></json:item><json:item><name>RW Tarnuzzer</name></json:item><json:item><name>MA Horan</name></json:item><json:item><name>GS Schultz</name></json:item><json:item><name>MW Fergunson</name></json:item></author><host><volume>3</volume><pages><last>1215</last><first>1209</first></pages><author></author><title>Nat Med</title></host><title>Estrogen accelerates cutaneous wound healing associated with an increase in TGF‐β1 levels</title></json:item><json:item><author><json:item><name>CR White</name></json:item><json:item><name>J Shelton</name></json:item><json:item><name>SJ Chen</name></json:item><json:item><name>V Darley‐Usmar</name></json:item><json:item><name>L Allen</name></json:item><json:item><name>C Nabors</name></json:item><json:item><name>PW Sanders</name></json:item><json:item><name>YF Chen</name></json:item><json:item><name>S Oparil</name></json:item></author><host><volume>96</volume><pages><last>1630</last><first>1624</first></pages><author></author><title>Circulation</title></host><title>Estrogen restores endothelial cell function in an experimental model of vascular injury</title></json:item><json:item><author><json:item><name>G New</name></json:item><json:item><name>JW Moses</name></json:item><json:item><name>GS Roubin</name></json:item><json:item><name>MB Leon</name></json:item><json:item><name>A Colombo</name></json:item><json:item><name>SS Iyer</name></json:item><json:item><name>FO Tio</name></json:item><json:item><name>R Mehran</name></json:item><json:item><name>N Kipshidze</name></json:item></author><host><volume>57</volume><pages><last>271</last><first>266</first></pages><author></author><title>Catheter Cardiovasc Interv</title></host><title>Estrogen‐eluting, phosphorylcholine‐coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model</title></json:item><json:item><author><json:item><name>F Airoldi</name></json:item><json:item><name>C Di Mario</name></json:item><json:item><name>F Ribichini</name></json:item><json:item><name>P Presbitero</name></json:item><json:item><name>P Sganzerla</name></json:item><json:item><name>F Ferreo</name></json:item><json:item><name>C Vassaneli</name></json:item><json:item><name>C Briguori</name></json:item><json:item><name>M Carlino</name></json:item><json:item><name>M Montorfano</name></json:item><json:item><name>GG Biondi‐Zoccai</name></json:item><json:item><name>A Chieffo</name></json:item><json:item><name>A Ferrari</name></json:item><json:item><name>A Colombo</name></json:item></author><host><volume>96</volume><pages><last>667</last><first>664</first></pages><author></author><title>Am J Cardiol</title></host><title>17‐β‐ estradiol eluting stent versus phosphorylcholine‐coated stent for the treatment of native coronary artery disease</title></json:item><json:item><author><json:item><name>CD Toran‐Allerand</name></json:item><json:item><name>AA Tinnikov</name></json:item><json:item><name>RJ Singh</name></json:item><json:item><name>IS Nethrapalli</name></json:item></author><host><volume>146</volume><pages><last>3850</last><first>3843</first></pages><author></author><title>Endocrinology</title></host><title>17α estradiol: A brain‐active estrogen?</title></json:item><json:item><author><json:item><name>P Concina</name></json:item><json:item><name>S Sordello</name></json:item><json:item><name>MA Barbacanne</name></json:item><json:item><name>R Elhage</name></json:item><json:item><name>MT Pieraggi</name></json:item><json:item><name>G Fournial</name></json:item><json:item><name>J Plouet</name></json:item><json:item><name>F Bayard</name></json:item><json:item><name>JF Arnal</name></json:item></author><host><volume>37</volume><pages><last>208</last><first>202</first></pages><author></author><title>J Vasc Res</title></host><title>The mitogenic effect of 17β‐estradiol on in vitro endothelial cell proliferation and on in vivo reendothelialization are both dependent on vascular endothelial growth factor</title></json:item><json:item><author><json:item><name>T Takao</name></json:item><json:item><name>C Kumagai</name></json:item><json:item><name>N Hisakawa</name></json:item><json:item><name>R Matsumoto</name></json:item><json:item><name>K Hashimoto</name></json:item></author><host><volume>184</volume><pages><last>197</last><first>191</first></pages><author></author><title>J Endocrinol</title></host><title>Effect of 17β‐estradiol on tumor necrosis factor‐α ‐induced cytotoxicity in the human peripheral T lymphocytes</title></json:item><json:item><author><json:item><name>KL Hamilton</name></json:item><json:item><name>FN Mbai</name></json:item><json:item><name>S Gupta</name></json:item><json:item><name>AA Knowlton</name></json:item></author><host><volume>24</volume><pages><last>1633</last><first>1628</first></pages><author></author><title>Arterioscler Thromb Vasc Biol</title></host><title>Estrogen, heat shock proteins, and NFκB in human vascular endothelium</title></json:item><json:item><author><json:item><name>CE Ihionkhan</name></json:item><json:item><name>KL Chambliss</name></json:item><json:item><name>LL Gibson</name></json:item><json:item><name>LD Hahner</name></json:item><json:item><name>ME Mendelsohn</name></json:item><json:item><name>PW Shaul</name></json:item></author><host><volume>91</volume><pages><last>820</last><first>814</first></pages><author></author><title>Circ Res</title></host><title>Estrogen causes dynamic alterations in endothelial estrogen receptor expression</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>70</volume><publisherId><json:string>CCD</json:string></publisherId><pages><total>7</total><last>660</last><first>654</first></pages><issn><json:string>1522-1946</json:string></issn><issue>5</issue><subject><json:item><value>Coronary Artery Disease</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1522-726X</json:string></eissn><title>Catheterization and Cardiovascular Interventions</title><doi><json:string>10.1002/(ISSN)1522-726X</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/ccd.21210</json:string></doi><id>2B9B796433B5D2406CAD4C00FB1CF8D69105D149</id><score>0.16002631</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/2B9B796433B5D2406CAD4C00FB1CF8D69105D149/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/2B9B796433B5D2406CAD4C00FB1CF8D69105D149/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2B9B796433B5D2406CAD4C00FB1CF8D69105D149/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2007 Wiley‐Liss, Inc.</p></availability><date>2007</date></publicationStmt><notesStmt><note>X‐Cell Medical</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial</title><author xml:id="author-1"><persName><forename type="first">Alexandre</forename><surname>Abizaid</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation><affiliation>Instituto Dante Pazzanese de Cardiologia, Av Dr Dante Pazzanese, 500, São Paulo 04012‐180, Brazil</affiliation></author><author xml:id="author-2"><persName><forename type="first">Áurea J.</forename><surname>Chaves</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation></author><author xml:id="author-3"><persName><forename type="first">Martin B.</forename><surname>Leon</surname></persName><roleName type="degree">MD</roleName><affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</affiliation><affiliation>Cardiovascular Research Foundation, New York, New York</affiliation></author><author xml:id="author-4"><persName><forename type="first">Karl</forename><surname>Hauptmann</surname></persName><roleName type="degree">MD</roleName><affiliation>Krankenhaus der Barmherzigen Brüder, Trier, Germany</affiliation></author><author xml:id="author-5"><persName><forename type="first">Roxana</forename><surname>Mehran</surname></persName><roleName type="degree">MD</roleName><affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</affiliation><affiliation>Cardiovascular Research Foundation, New York, New York</affiliation></author><author xml:id="author-6"><persName><forename type="first">Alexandra J.</forename><surname>Lansky</surname></persName><roleName type="degree">MD</roleName><affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</affiliation><affiliation>Cardiovascular Research Foundation, New York, New York</affiliation></author><author xml:id="author-7"><persName><forename type="first">William</forename><surname>Baumbach</surname></persName><roleName type="degree">PhD</roleName><affiliation>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</affiliation></author><author xml:id="author-8"><persName><forename type="first">Hari</forename><surname>Shankar</surname></persName><roleName type="degree">PhD</roleName><affiliation>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</affiliation></author><author xml:id="author-9"><persName><forename type="first">Ralf</forename><surname>Muller</surname></persName><roleName type="degree">MD</roleName><affiliation>Heart Center Siegburg, Siegburg, Germany</affiliation></author><author xml:id="author-10"><persName><forename type="first">Fausto</forename><surname>Feres</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation></author><author xml:id="author-11"><persName><forename type="first">Amanda G.M.R.</forename><surname>Sousa</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation></author><author xml:id="author-12"><persName><forename type="first">J. Eduardo</forename><surname>Sousa</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation></author><author xml:id="author-13"><persName><forename type="first">Eberhard</forename><surname>Grube</surname></persName><roleName type="degree">MD</roleName><affiliation>Heart Center Siegburg, Siegburg, Germany</affiliation></author></analytic><monogr><title level="j">Catheterization and Cardiovascular Interventions</title><title level="j" type="abbrev">Cathet. Cardiovasc. Intervent.</title><idno type="pISSN">1522-1946</idno><idno type="eISSN">1522-726X</idno><idno type="DOI">10.1002/(ISSN)1522-726X</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-11-01"></date><biblScope unit="volume">70</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="654">654</biblScope><biblScope unit="page" to="660">660</biblScope></imprint></monogr><idno type="istex">2B9B796433B5D2406CAD4C00FB1CF8D69105D149</idno><idno type="DOI">10.1002/ccd.21210</idno><idno type="ArticleID">CCD21210</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Objectives: The ETHOS I trial was the first in‐human experience evaluating the safety and efficacy of two different release formulations of the 17‐β estradiol‐eluting R‐Stent™ versus uncoated control stents for the treatment of patients with single de novo native coronary lesions. Background: Estrogens were reported to inhibit neointimal proliferation and to accelerate endothelial regeneration after coronary angioplasty and thus could be an ideal compound to deliver on a stent for the purpose of reducing in‐stent restenosis. Methods: Ninety‐five patients were randomized to receive a slow‐release (n = 32) or the moderate release (n = 31) formulations or the bare metal stent (n = 32). The primary end point was the 6‐month percent in‐stent volume obstruction by intravascular ultrasound (IVUS). Results: Diabetes was present in 29.5% of patients; the mean reference vessel diameter was 2.90 mm; and the mean lesion length was 13.5 mm. Primary endpoint, 6‐month percent in‐stent volume obstruction by IVUS, did not differ significantly between the 3 groups (31% ± 14%, 33% ± 11%, and 31% ± 14%, P = 0.83). Secondary endpoints also did not differ significantly between the groups including 6‐month rates of in‐lesion binary angiographic restenosis (13.3%, 14.3%, and 12.5%, P = 0.98), in‐stent late loss (0.82 ± 0.49 mm, 0.86 ± 0.53 mm, and 0.84 ± 0.46 mm, P = 0.97), target lesion revascularization (12.5%, 6.9%, and 6.5%, P = 0.64), and major adverse cardiac events (18.8%, 10.3%, and 6.5%, P = 0.31). Conclusions: In this first‐in‐man randomized trial, the 17‐β estradiol‐eluting R‐Stent™, in either slow‐ or moderate‐release formulations, was well‐tolerated, but showed no benefit for treatment of coronary lesions when compared to controls. © 2007 Wiley‐Liss, Inc.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>coronary artery disease</term></item><item><term>drug‐eluting stents</term></item><item><term>restenosis</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Coronary Artery Disease</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-02-01">Received</change><change when="2007-03-23">Registration</change><change when="2007-11-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/2B9B796433B5D2406CAD4C00FB1CF8D69105D149/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1522-726X</doi><issn type="print">1522-1946</issn><issn type="electronic">1522-726X</issn><idGroup><id type="product" value="CCD"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS">Catheterization and Cardiovascular Interventions</title><title type="short">Cathet. Cardiovasc. Intervent.</title></titleGroup><selfCitationGroup><citation type="ancestor" xml:id="cit1"><journalTitle>Catheterization and Cardiovascular Diagnosis</journalTitle><accessionId ref="info:x-wiley/issn/00986569">0098-6569</accessionId><accessionId ref="info:x-wiley/issn/10970304">1097-0304</accessionId><pubYear year="1998">1998</pubYear><vol>45</vol><issue>4</issue></citation></selfCitationGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/ccd.v70:5</doi><numberingGroup><numbering type="journalVolume" number="70">70</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2007-11-01">1 November 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="8" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ccd.21210</doi><idGroup><id type="unit" value="CCD21210"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Coronary Artery Disease</title><title type="tocHeading1">Coronary Artery Diseases</title><title type="tocHeading2">Original Studies</title></titleGroup><copyright ownership="publisher">Copyright © 2007 Wiley‐Liss, Inc.</copyright><eventGroup><event type="manuscriptReceived" date="2007-02-01"></event><event type="manuscriptAccepted" date="2007-03-23"></event><event type="publishedOnlineEarlyUnpaginated" date="2007-10-11"></event><event type="firstOnline" date="2007-10-11"></event><event type="publishedOnlineFinalForm" date="2007-10-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.15 mode:FullText" date="2010-07-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-09"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-15"></event></eventGroup><numberingGroup><numbering type="pageFirst">654</numbering><numbering type="pageLast">660</numbering></numberingGroup><correspondenceTo>Instituto Dante Pazzanese de Cardiologia, Av Dr Dante Pazzanese, 500, São Paulo 04012‐180, Brazil</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:CCD.CCD21210.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="5"></count><count type="referenceTotal" number="23"></count><count type="wordTotal" number="5926"></count></countGroup><titleGroup><title type="main" xml:lang="en">Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial</title><title type="short" xml:lang="en">Ethos I Trial</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Alexandre</givenNames><familyName>Abizaid</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>aabizaid@uol.com.br</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Áurea J.</givenNames><familyName>Chaves</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2 #af3"><personName><givenNames>Martin B.</givenNames><familyName>Leon</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Karl</givenNames><familyName>Hauptmann</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2 #af3"><personName><givenNames>Roxana</givenNames><familyName>Mehran</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2 #af3"><personName><givenNames>Alexandra J.</givenNames><familyName>Lansky</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af5"><personName><givenNames>William</givenNames><familyName>Baumbach</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Hari</givenNames><familyName>Shankar</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Ralf</givenNames><familyName>Muller</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Fausto</givenNames><familyName>Feres</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Amanda G.M.R.</givenNames><familyName>Sousa</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af1"><personName><givenNames>J. Eduardo</givenNames><familyName>Sousa</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Eberhard</givenNames><familyName>Grube</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="BR" type="organization"><unparsedAffiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>College of Physicians and Surgeons, Columbia University, New York, New York</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Cardiovascular Research Foundation, New York, New York</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="DE" type="organization"><unparsedAffiliation>Krankenhaus der Barmherzigen Brüder, Trier, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="DE" type="organization"><unparsedAffiliation>Heart Center Siegburg, Siegburg, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">coronary artery disease</keyword><keyword xml:id="kwd2">drug‐eluting stents</keyword><keyword xml:id="kwd3">restenosis</keyword></keywordGroup><fundingInfo><fundingAgency>X‐Cell Medical</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p><span cssStyle="text-decoration:underline">Objectives</span>: The ETHOS I trial was the first in‐human experience evaluating the safety and efficacy of two different release formulations of the 17‐β estradiol‐eluting R‐Stent™ versus uncoated control stents for the treatment of patients with single de novo native coronary lesions. <span cssStyle="text-decoration:underline">Background</span>: Estrogens were reported to inhibit neointimal proliferation and to accelerate endothelial regeneration after coronary angioplasty and thus could be an ideal compound to deliver on a stent for the purpose of reducing in‐stent restenosis. <span cssStyle="text-decoration:underline">Methods</span>: Ninety‐five patients were randomized to receive a slow‐release (<i>n</i> = 32) or the moderate release (<i>n</i> = 31) formulations or the bare metal stent (<i>n</i> = 32). The primary end point was the 6‐month percent in‐stent volume obstruction by intravascular ultrasound (IVUS). <span cssStyle="text-decoration:underline">Results</span>: Diabetes was present in 29.5% of patients; the mean reference vessel diameter was 2.90 mm; and the mean lesion length was 13.5 mm. Primary endpoint, 6‐month percent in‐stent volume obstruction by IVUS, did not differ significantly between the 3 groups (31% ± 14%, 33% ± 11%, and 31% ± 14%, <i>P</i> = 0.83). Secondary endpoints also did not differ significantly between the groups including 6‐month rates of in‐lesion binary angiographic restenosis (13.3%, 14.3%, and 12.5%, <i>P</i> = 0.98), in‐stent late loss (0.82 ± 0.49 mm, 0.86 ± 0.53 mm, and 0.84 ± 0.46 mm, <i>P</i> = 0.97), target lesion revascularization (12.5%, 6.9%, and 6.5%, <i>P</i> = 0.64), and major adverse cardiac events (18.8%, 10.3%, and 6.5%, <i>P</i> = 0.31). <span cssStyle="text-decoration:underline">Conclusions</span>: In this first‐in‐man randomized trial, the 17‐β estradiol‐eluting R‐Stent™, in either slow‐ or moderate‐release formulations, was well‐tolerated, but showed no benefit for treatment of coronary lesions when compared to controls. © 2007 Wiley‐Liss, Inc.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Ethos I Trial</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial</title></titleInfo><name type="personal"><namePart type="given">Alexandre</namePart><namePart type="family">Abizaid</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation><affiliation>Instituto Dante Pazzanese de Cardiologia, Av Dr Dante Pazzanese, 500, São Paulo 04012‐180, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Áurea J.</namePart><namePart type="family">Chaves</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin B.</namePart><namePart type="family">Leon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</affiliation><affiliation>Cardiovascular Research Foundation, New York, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karl</namePart><namePart type="family">Hauptmann</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Krankenhaus der Barmherzigen Brüder, Trier, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Roxana</namePart><namePart type="family">Mehran</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</affiliation><affiliation>Cardiovascular Research Foundation, New York, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexandra J.</namePart><namePart type="family">Lansky</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>College of Physicians and Surgeons, Columbia University, New York, New York</affiliation><affiliation>Cardiovascular Research Foundation, New York, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William</namePart><namePart type="family">Baumbach</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hari</namePart><namePart type="family">Shankar</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>X‐Cell Medical, Inc., Monmouth Junction, New Jersey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ralf</namePart><namePart type="family">Muller</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Heart Center Siegburg, Siegburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fausto</namePart><namePart type="family">Feres</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Amanda G.M.R.</namePart><namePart type="family">Sousa</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. Eduardo</namePart><namePart type="family">Sousa</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eberhard</namePart><namePart type="family">Grube</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Heart Center Siegburg, Siegburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-11-01</dateIssued><dateCaptured encoding="w3cdtf">2007-02-01</dateCaptured><dateValid encoding="w3cdtf">2007-03-23</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">5</extent><extent unit="references">23</extent><extent unit="words">5926</extent></physicalDescription><abstract lang="en">Objectives: The ETHOS I trial was the first in‐human experience evaluating the safety and efficacy of two different release formulations of the 17‐β estradiol‐eluting R‐Stent™ versus uncoated control stents for the treatment of patients with single de novo native coronary lesions. Background: Estrogens were reported to inhibit neointimal proliferation and to accelerate endothelial regeneration after coronary angioplasty and thus could be an ideal compound to deliver on a stent for the purpose of reducing in‐stent restenosis. Methods: Ninety‐five patients were randomized to receive a slow‐release (n = 32) or the moderate release (n = 31) formulations or the bare metal stent (n = 32). The primary end point was the 6‐month percent in‐stent volume obstruction by intravascular ultrasound (IVUS). Results: Diabetes was present in 29.5% of patients; the mean reference vessel diameter was 2.90 mm; and the mean lesion length was 13.5 mm. Primary endpoint, 6‐month percent in‐stent volume obstruction by IVUS, did not differ significantly between the 3 groups (31% ± 14%, 33% ± 11%, and 31% ± 14%, P = 0.83). Secondary endpoints also did not differ significantly between the groups including 6‐month rates of in‐lesion binary angiographic restenosis (13.3%, 14.3%, and 12.5%, P = 0.98), in‐stent late loss (0.82 ± 0.49 mm, 0.86 ± 0.53 mm, and 0.84 ± 0.46 mm, P = 0.97), target lesion revascularization (12.5%, 6.9%, and 6.5%, P = 0.64), and major adverse cardiac events (18.8%, 10.3%, and 6.5%, P = 0.31). Conclusions: In this first‐in‐man randomized trial, the 17‐β estradiol‐eluting R‐Stent™, in either slow‐ or moderate‐release formulations, was well‐tolerated, but showed no benefit for treatment of coronary lesions when compared to controls. © 2007 Wiley‐Liss, Inc.</abstract><note type="funding">X‐Cell Medical</note><subject lang="en"><genre>keywords</genre><topic>coronary artery disease</topic><topic>drug‐eluting stents</topic><topic>restenosis</topic></subject><relatedItem type="host"><titleInfo><title>Catheterization and Cardiovascular Interventions</title></titleInfo><titleInfo type="abbreviated"><title>Cathet. Cardiovasc. Intervent.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Coronary Artery Disease</topic></subject><identifier type="ISSN">1522-1946</identifier><identifier type="eISSN">1522-726X</identifier><identifier type="DOI">10.1002/(ISSN)1522-726X</identifier><identifier type="PublisherID">CCD</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>654</start><end>660</end><total>7</total></extent></part></relatedItem><relatedItem type="preceding"><titleInfo><title>Catheterization and Cardiovascular Diagnosis</title></titleInfo><identifier type="ISSN">0098-6569</identifier><identifier type="ISSN">1097-0304</identifier><part><date point="end">1998</date><detail type="volume"><caption>last vol.</caption><number>45</number></detail><detail type="issue"><caption>last no.</caption><number>4</number></detail></part></relatedItem><identifier type="istex">2B9B796433B5D2406CAD4C00FB1CF8D69105D149</identifier><identifier type="DOI">10.1002/ccd.21210</identifier><identifier type="ArticleID">CCD21210</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001507 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001507 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2B9B796433B5D2406CAD4C00FB1CF8D69105D149
|texte= Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial
}}
| This area was generated with Dilib version V0.6.31. |  |